Initial Clinical Data From the Ongoing Clinical Trial of CFT1946
Time: 8:30 am
day: Day Two AM
Details:
NEW DATA
- Well-tolerated at all dose levels; no dose-limiting toxicities
- Dose proportional pharmacokinetic exposure; successfully degrades BRAF V600 mutant protein
- Early evidence of CFT1946 monotherapy anti-tumor activity in patients who have progressed on or after BRAF inhibitor therapies
- Preclinical data demonstrating blood-brain barrier permeability
